Abeona Therapeutics Inc (NASDAQ:ABEO) traded down 7.9% during trading on Monday . The stock traded as low as $14.50 and last traded at $15.20. 1,262,178 shares traded hands during trading, an increase of 96% from the average session volume of 645,284 shares. The stock had previously closed at $16.50.

Several equities research analysts have recently commented on the company. Cantor Fitzgerald upped their target price on Abeona Therapeutics from $21.00 to $34.00 and gave the company an “overweight” rating in a report on Wednesday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price (up from $20.00) on shares of Abeona Therapeutics in a report on Monday, October 9th. Citigroup assumed coverage on Abeona Therapeutics in a report on Tuesday, October 10th. They set a “buy” rating and a $32.00 target price for the company. ValuEngine downgraded Abeona Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, Jefferies Group reaffirmed a “buy” rating and set a $28.00 target price on shares of Abeona Therapeutics in a report on Wednesday, November 22nd. One analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $26.10.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Wednesday, November 15th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.18) by $0.05. Abeona Therapeutics had a negative return on equity of 27.69% and a negative net margin of 2,946.58%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.22 million. analysts predict that Abeona Therapeutics Inc will post -0.6 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the company. State of Wisconsin Investment Board acquired a new position in shares of Abeona Therapeutics during the 2nd quarter valued at about $122,000. Rhumbline Advisers acquired a new stake in Abeona Therapeutics in the 2nd quarter valued at approximately $190,000. Schwab Charles Investment Management Inc. acquired a new stake in Abeona Therapeutics in the 2nd quarter valued at approximately $264,000. California State Teachers Retirement System acquired a new stake in Abeona Therapeutics in the 2nd quarter valued at approximately $275,000. Finally, Teachers Advisors LLC acquired a new stake in Abeona Therapeutics in the 2nd quarter valued at approximately $284,000. 41.95% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/12/20/abeona-therapeutics-abeo-shares-down-7-9.html.

About Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.